Abstract:The Journal of Clinical PharmacologyAccepted Articles COMMENTARYFree Access Exploring the knowledge gaps in infant drug exposure from human milk: A clinical pharmacology perspective Daphne Guinn PhD, Corresponding Author Daphne Guinn PhD Daphne.Guinn@fda.hhs.gov Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA Correspondence Daphne Guinn, PhD, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Email: Daphne.Guinn@fda.hhs.govSearch for more papers by this authorMichelle A. Pressly PhD, Michelle A. Pressly PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorZhichao Liu PhD, Zhichao Liu PhD National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas, USASearch for more papers by this authorCarrie Ceresa PharmDMPH, Carrie Ceresa PharmDMPH Division of Pediatrics and Maternal Health, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Office of New Drugs, Center for Drug Evaluation and Research, Silver Spring, Maryland, USASearch for more papers by this authorSherbet Samuels PhD, Sherbet Samuels PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorYow-Ming Wang PhD, Yow-Ming Wang PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorRajanikanth Madabushi PhD, Rajanikanth Madabushi PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorStephan Schmidt PhD, Stephan Schmidt PhD Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, United StatesSearch for more papers by this authorElimika Pfuma Fletcher PharmDPhD, Elimika Pfuma Fletcher PharmDPhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this author Daphne Guinn PhD, Corresponding Author Daphne Guinn PhD Daphne.Guinn@fda.hhs.gov Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA Correspondence Daphne Guinn, PhD, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Email: Daphne.Guinn@fda.hhs.govSearch for more papers by this authorMichelle A. Pressly PhD, Michelle A. Pressly PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorZhichao Liu PhD, Zhichao Liu PhD National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas, USASearch for more papers by this authorCarrie Ceresa PharmDMPH, Carrie Ceresa PharmDMPH Division of Pediatrics and Maternal Health, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Office of New Drugs, Center for Drug Evaluation and Research, Silver Spring, Maryland, USASearch for more papers by this authorSherbet Samuels PhD, Sherbet Samuels PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorYow-Ming Wang PhD, Yow-Ming Wang PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorRajanikanth Madabushi PhD, Rajanikanth Madabushi PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorStephan Schmidt PhD, Stephan Schmidt PhD Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, United StatesSearch for more papers by this authorElimika Pfuma Fletcher PharmDPhD, Elimika Pfuma Fletcher PharmDPhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this author First published: 10 November 2022 https://doi.org/10.1002/jcph.2177 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as https://doi.org/10.1002/jcph.2177 AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Accepted ArticlesAccepted, unedited articles published online and citable. The final edited and typeset version of record will appear in the future. RelatedInformation

Plasticity of Fetal and Adult Cns Serotonergic Neurons - Role of Growth-Regulatory Factors

Several Concerns Arise when the Results Are Interpreted

Sex-biased Effects on Hippocampal Circuit Development by Perinatal SERT Expression in CA3 Pyramidal Neurons.

New Insights into How Serotonin Selective Reuptake Inhibitors Shape the Developing Brain

Correction to “in Utero Exposure to Citalopram Mitigates Maternal Stress Effects on Fetal Brain Development”

Neuroplasticity May Play A Role in Inter-Individual Difference among Neuropsychiatric Disease Treatment Efficacy

Structural Studies on McN‐5652‐X (I), a High‐Affinity Ligand for the Serotonin Transporter in Mammalian Brain.

Serotonin homeostasis in the materno‐foetal interface at term: Role of transporters (SERT/SLC6A4 and OCT3/SLC22A3) and monoamine oxidase A (MAO‐A) in uptake and degradation of serotonin by human and rat term placenta

Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression

Refining the Role of 5-HT in Postnatal Development of Brain Circuits

Growth-Hormone Receptors - Their Structure, Location And Role

Serotonin Depletion Hampers Survival and Proliferation in Neurospheres Derived from Adult Neural Stem Cells

Synthesis and Pharmacological Evaluation of (z)‐9‐(heteroarylmethylene)‐7‐azatricyclo[4.3.1.03,7]decanes: Thiophene Analogues As Potent Norepinephrine Transporter Inhibitors.

Enhancing Depression Mechanisms in Midbrain Dopamine Neurons

Perinatal serotonin signalling dynamically influences the development of cortical GABAergic circuits with consequences for lifelong sensory encoding

Assessing the Neurodevelopmental Impact of Fluoxetine, Citalopram, and Paroxetine on Neural Stem Cell-Derived Neurons

Symposium S04: Frontiers in Embryonic Stem Cell Research

Postnatal Day 2 to 11 Constitutes a 5-HT-Sensitive Period Impacting Adult mPFC Function

SSRIs target prefrontal to raphe circuits during development modulating synaptic connectivity and emotional behavior

Serotonin modulates excitatory synapse maturation in the developing prefrontal cortex

Exploring the Knowledge Gaps in Infant Drug Exposure from Human Milk: A Clinical Pharmacology Perspective